Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Satralizumab Monotherapy in NMOSD (SAkuraStar)
NCT02073279Phase 3Completed
- Sponsor
- Roche
- Start
- Aug 2014
- Primary completion
- Oct 2018
- Modality
- Monoclonal Antibodies
- Countries
- 15
01
Overview
Phase 3, randomised, double-blind trial in neuromyelitis optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD) comparing Satralizumab with Placebo (2 arms). Primary endpoint: Time to First Protocol-Defined Relapse. Started Aug 2014; status: completed.
02
Drugs
satralizumab
03
Conditions
neuromyelitis optica (NMO)Neuromyelitis Optica Spectrum Disorder (NMOSD)
Beyond the preview
Go deeper on NCT02073279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02073279.